Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab : a case report
BACKGROUND: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.
CASE PRESENTATION: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.
CONCLUSION: This case suggests new perspectives for the treatment of asbestosis and its systemic features.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
BMC musculoskeletal disorders - 16(2015) vom: 14. Juni, Seite 146 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Niccoli, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37CQ2C7X93 |
|---|
| Anmerkungen: |
Date Completed 04.02.2016 Date Revised 10.12.2019 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12891-015-0602-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM249933403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM249933403 | ||
| 003 | DE-627 | ||
| 005 | 20231224154641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12891-015-0602-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0833.xml |
| 035 | |a (DE-627)NLM249933403 | ||
| 035 | |a (NLM)26071911 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Niccoli, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab |b a case report |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2016 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported | ||
| 520 | |a CASE PRESENTATION: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months | ||
| 520 | |a CONCLUSION: This case suggests new perspectives for the treatment of asbestosis and its systemic features | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a canakinumab |2 NLM | |
| 650 | 7 | |a 37CQ2C7X93 |2 NLM | |
| 700 | 1 | |a Cassarà, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Kaloudi, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Nannini, Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnoli, Micaela |e verfasserin |4 aut | |
| 700 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC musculoskeletal disorders |d 2000 |g 16(2015) vom: 14. Juni, Seite 146 |w (DE-627)NLM111431875 |x 1471-2474 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2015 |g day:14 |g month:06 |g pages:146 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12891-015-0602-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2015 |b 14 |c 06 |h 146 | ||